American Shared Hospital Services (AMS)
Market Price (5/11/2026): $1.87 | Market Cap: $12.5 MilSector: Health Care | Industry: Health Care Facilities
American Shared Hospital Services (AMS)
Market Price (5/11/2026): $1.87Market Cap: $12.5 MilSector: Health CareIndustry: Health Care Facilities
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 11% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, and Oncology Treatments. | Weak multi-year price returns2Y Excs Rtn is -81%, 3Y Excs Rtn is -114% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -2.0 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -7.2% Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 152% Weak revenue growthRev Chg QQuarterly Revenue Change % is -15% Not cash flow generativeFCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -23% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -16% Key risksAMS key risks include [1] a lender default threatening its immediate liquidity, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 11% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, and Oncology Treatments. |
| Weak multi-year price returns2Y Excs Rtn is -81%, 3Y Excs Rtn is -114% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -2.0 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -7.2% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 152% |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -15% |
| Not cash flow generativeFCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -23% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -16% |
| Key risksAMS key risks include [1] a lender default threatening its immediate liquidity, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Significant Miss in Q4 2025 Earnings and Revenue. American Shared Hospital Services reported a net loss of $0.09 per diluted share for Q4 2025, missing analysts' consensus estimates of a $0.02 EPS by $0.11. Additionally, quarterly revenue came in at $7.73 million, falling below analysts' expectations of $8.78 million and representing a 14.8% decrease from the prior period. This performance significantly impacted investor sentiment.
2. Decline in Medical Equipment Leasing Revenue Due to Contract Expirations. A core reason for the revenue decline was a 33.9% decrease in revenue from the medical equipment leasing segment in Q4 2025, primarily driven by the expiration of three Gamma Knife contracts and lower proton beam radiation therapy (PBRT) volumes. This highlights challenges in retaining and securing new leasing agreements.
Show more
Stock Movement Drivers
Fundamental Drivers
The -11.8% change in AMS stock from 1/31/2026 to 5/11/2026 was primarily driven by a -6.8% change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 5112026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.12 | 1.87 | -11.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 29 | 28 | -4.6% |
| P/S Multiple | 0.5 | 0.4 | -6.8% |
| Shares Outstanding (Mil) | 7 | 7 | -0.8% |
| Cumulative Contribution | -11.8% |
Market Drivers
1/31/2026 to 5/11/2026| Return | Correlation | |
|---|---|---|
| AMS | -10.8% | |
| Market (SPY) | 3.6% | -22.2% |
| Sector (XLV) | -7.2% | -11.0% |
Fundamental Drivers
The -17.3% change in AMS stock from 10/31/2025 to 5/11/2026 was primarily driven by a -12.5% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 5112026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.26 | 1.87 | -17.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 29 | 28 | -4.0% |
| P/S Multiple | 0.5 | 0.4 | -12.5% |
| Shares Outstanding (Mil) | 7 | 7 | -1.5% |
| Cumulative Contribution | -17.3% |
Market Drivers
10/31/2025 to 5/11/2026| Return | Correlation | |
|---|---|---|
| AMS | -16.4% | |
| Market (SPY) | 5.5% | -14.6% |
| Sector (XLV) | -0.0% | -3.0% |
Fundamental Drivers
The -30.7% change in AMS stock from 4/30/2025 to 5/11/2026 was primarily driven by a -28.6% change in the company's P/S Multiple.| (LTM values as of) | 4302025 | 5112026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.70 | 1.87 | -30.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 28 | 28 | -0.9% |
| P/S Multiple | 0.6 | 0.4 | -28.6% |
| Shares Outstanding (Mil) | 7 | 7 | -2.1% |
| Cumulative Contribution | -30.7% |
Market Drivers
4/30/2025 to 5/11/2026| Return | Correlation | |
|---|---|---|
| AMS | -30.0% | |
| Market (SPY) | 30.4% | -4.5% |
| Sector (XLV) | 3.6% | -13.9% |
Fundamental Drivers
The -32.7% change in AMS stock from 4/30/2023 to 5/11/2026 was primarily driven by a -51.5% change in the company's P/S Multiple.| (LTM values as of) | 4302023 | 5112026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.78 | 1.87 | -32.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 20 | 28 | 42.2% |
| P/S Multiple | 0.9 | 0.4 | -51.5% |
| Shares Outstanding (Mil) | 7 | 7 | -2.5% |
| Cumulative Contribution | -32.7% |
Market Drivers
4/30/2023 to 5/11/2026| Return | Correlation | |
|---|---|---|
| AMS | -32.0% | |
| Market (SPY) | 78.7% | 1.6% |
| Sector (XLV) | 12.6% | -6.2% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| AMS Return | 7% | 24% | -19% | 34% | -34% | -4% | -9% |
| Peers Return | 39% | 2% | 18% | 13% | 21% | 9% | 149% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 97% |
Monthly Win Rates [3] | |||||||
| AMS Win Rate | 50% | 58% | 50% | 67% | 17% | 40% | |
| Peers Win Rate | 63% | 53% | 57% | 53% | 62% | 40% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| AMS Max Drawdown | -3% | -11% | -25% | 0% | -36% | -39% | |
| Peers Max Drawdown | -6% | -31% | -10% | -11% | -20% | -13% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ACHC, HCA, THC, ENSG, UHS.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/11/2026 (YTD)
How Low Can It Go
| Event | AMS | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -18.4% | -18.8% |
| % Gain to Breakeven | 22.6% | 23.1% |
| Time to Breakeven | 126 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -11.3% | -7.8% |
| % Gain to Breakeven | 12.7% | 8.5% |
| Time to Breakeven | 6 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -19.1% | -9.5% |
| % Gain to Breakeven | 23.6% | 10.5% |
| Time to Breakeven | 71 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -23.7% | -6.7% |
| % Gain to Breakeven | 31.0% | 7.1% |
| Time to Breakeven | 298 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -12.1% | -24.5% |
| % Gain to Breakeven | 13.7% | 32.4% |
| Time to Breakeven | 1 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -47.7% | -33.7% |
| % Gain to Breakeven | 91.3% | 50.9% |
| Time to Breakeven | 90 days | 140 days |
In The Past
American Shared Hospital Services's stock fell -18.4% during the 2025 US Tariff Shock. Such a loss loss requires a 22.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | AMS | S&P 500 |
|---|---|---|
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -23.7% | -6.7% |
| % Gain to Breakeven | 31.0% | 7.1% |
| Time to Breakeven | 298 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -47.7% | -33.7% |
| % Gain to Breakeven | 91.3% | 50.9% |
| Time to Breakeven | 90 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -40.2% | -19.2% |
| % Gain to Breakeven | 67.1% | 23.7% |
| Time to Breakeven | 860 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -39.6% | -12.2% |
| % Gain to Breakeven | 65.6% | 13.9% |
| Time to Breakeven | 104 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -34.3% | -6.8% |
| % Gain to Breakeven | 52.1% | 7.3% |
| Time to Breakeven | 99 days | 15 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -20.3% | -17.9% |
| % Gain to Breakeven | 25.5% | 21.8% |
| Time to Breakeven | 161 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -54.8% | -53.4% |
| % Gain to Breakeven | 121.1% | 114.4% |
| Time to Breakeven | 86 days | 1085 days |
In The Past
American Shared Hospital Services's stock fell -18.4% during the 2025 US Tariff Shock. Such a loss loss requires a 22.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About American Shared Hospital Services (AMS)
AI Analysis | Feedback
Like Xerox, but instead of office copiers, they lease extremely advanced radiosurgery and radiation therapy equipment to hospitals.
A "Netflix for advanced cancer treatment equipment," providing hospitals with access to cutting-edge radiosurgery and radiation therapy machines without the massive upfront purchase.
AI Analysis | Feedback
- Gamma Knife Equipment Leasing: Leases radiosurgery equipment, specifically Gamma Knife units, to healthcare providers for non-invasive brain treatments.
- Gamma Knife Unit Financing: Provides financing services specifically for Leksell Gamma Knife units.
- Proton Beam Radiation Therapy (PBRT) Services: Offers direct proton beam radiation therapy services at facilities in Orlando, Florida, and Long Beach, California.
- Customer Support Services: Provides planning, installation, reimbursement, and marketing support to its healthcare provider customers.
AI Analysis | Feedback
American Shared Hospital Services (AMS) primarily sells to other companies, specifically various types of health care providers.
Its major customers are:
- Hospitals: Large medical institutions that utilize AMS's radiosurgery and radiation therapy equipment, such as Gamma Knife units and Proton Beam Radiation Therapy (PBRT) systems, to provide advanced treatments to their patients.
- Medical Centers/Clinics: Specialized medical facilities that offer radiation oncology or neurosurgery services and lease equipment from AMS to expand their treatment capabilities.
AI Analysis | Feedback
- Elekta AB (STO: EKTA B)
- Mevion Medical Systems, Inc.
AI Analysis | Feedback
Ray Stachowiak, Executive Chairman and Chief Executive Officer Ray Stachowiak assumed the role of Executive Chairman and Chief Executive Officer of American Shared Hospital Services in April 2024, following the passing of the previous CEO. He previously served as CEO from October 2020 and as Interim President and CEO from May 2020. Mr. Stachowiak has been a Director of the company since 2009. He is also noted as the founder and owner of Shared Imaging. Bob Hiatt, Chief Financial Officer Bob Hiatt serves as the Chief Financial Officer for American Shared Hospital Services, a role he continued in as of April 2024. Gary Delanois, Executive Vice President and Chief Operating Officer Gary Delanois was appointed Executive Vice President and Chief Operating Officer in October 2024. He brings over 28 years of progressive healthcare management experience, providing solutions to Physician Groups, Health Systems, ACO's, and Health Plans. Mr. Delanois's background includes deep experience with physician and payor relationships, as well as billing and collection policies. He previously served as CEO of HCA Physician Services of SWFL and is a Certified Public Accountant (inactive). Craig K. Tagawa, President Craig K. Tagawa was promoted to President and Chief Operating Officer in April 2024. Given Gary Delanois's appointment as EVP and COO in October 2024, Mr. Tagawa is likely currently serving as President. He has been with American Shared Hospital Services since 1988 and served as CFO since 1992. Ranjit Pradhan, Senior Vice President of Sales and Marketing Ranjit Pradhan was promoted to Senior Vice President of Sales and Marketing in October 2024. He previously held the title of Head of Marketing and Customer Advocacy, and Vice President of Customer Advocacy and Global Marketing. Mr. Pradhan has 30 years of experience in healthcare, with roles spanning product management, marketing, technology, and general management at Fortune 100 and global companies such as GE, Abbott, Elekta, Sysmex, and Philips. He also has senior leadership and advisor positions with startups.AI Analysis | Feedback
The key risks to American Shared Hospital Services (AMS) are primarily related to external regulatory and market dynamics, the inherent nature of leasing advanced medical technology, and its financial health.- Changes to CMS Reimbursement Rates or Methodology: A significant portion of the company's revenue and the demand for its equipment leasing and direct patient care services are dependent on reimbursement rates from government programs like Medicare (Centers for Medicare & Medicaid Services - CMS) and private insurers. Unfavorable changes to these rates or the methodologies used for reimbursement for Gamma Knife, proton therapy, and other advanced radiation therapy services could directly and adversely impact the profitability of American Shared Hospital Services and its healthcare provider partners, thereby affecting AMS's business model and financial results.
- Technological Obsolescence and Intense Competition: American Shared Hospital Services leases state-of-the-art radiosurgery and radiation therapy equipment, such as Gamma Knife and Proton Beam Radiation Therapy (PBRT) systems. The rapid pace of technological advancements in the medical equipment industry poses a risk that the company's existing equipment could become outdated or less competitive. While American Shared Hospital Services' business model often transfers the risk of technological obsolescence from the medical center to the company, this means AMS itself bears the burden of ensuring its offerings remain current and competitive. The market for these advanced therapies is also subject to intense competition from other equipment providers and alternative treatment modalities, which could impact demand for AMS's services.
- Financing and Liquidity Risks: American Shared Hospital Services operates in a capital-intensive industry, requiring substantial investment in medical equipment. The company's ability to maintain and expand its equipment fleet, as well as its overall operations, is dependent on access to financing and maintaining sufficient liquidity. A notable risk in this area is evidenced by the company receiving a notice of default from its lender in December 2025 due to failing to maintain required minimum unrestricted cash and cash equivalents. This highlights the criticality of managing debt obligations and maintaining adequate financial resources.
AI Analysis | Feedback
nullAI Analysis | Feedback
American Shared Hospital Services (AMS) operates in two primary addressable markets: radiosurgery equipment leasing, specifically for Gamma Knife stereotactic radiosurgery, and proton beam radiation therapy (PBRT) services.
Gamma Knife Stereotactic Radiosurgery Market
The global market for Gamma Knife is valued at several hundred million U.S. dollars. In 2024, the global Gamma Knife market size was approximately USD 468.22 million and is projected to reach USD 691.78 million by 2032, exhibiting a compound annual growth rate (CAGR) of 5.00%. Another report estimated the global Gamma Knife market at USD 470.3 million in 2023, with a projection to reach USD 742.3 million by 2033 at a CAGR of 5.2%.
North America is a significant region in the global Gamma Knife market, expected to hold the largest market share, with the U.S. being a leading contributor due to advanced neurosurgical infrastructure and high healthcare spending.
Proton Beam Radiation Therapy Market
The global market for proton therapy, including systems and services, is considerably larger, valued in the billions of U.S. dollars. The global proton therapy systems market size was US$ 1.52 billion in 2024 and is forecast to rise to US$ 1.66 billion by 2025. It is expected to surpass US$ 3.72 billion by 2034, growing at a CAGR of 9.44%. Other estimates place the global proton therapy market at approximately USD 572.5 million in 2024, projected to reach around USD 1,995.62 million by 2034 with a CAGR of 13.30%. Additionally, the global proton therapy market was valued at USD 1.57 billion in 2023 and is predicted to grow to around USD 5.86 billion by 2032.
North America is a dominant region in the proton therapy market. In 2024, North America held approximately 40% of the proton therapy systems market revenue share. The North America proton therapy market size was calculated at USD 246.18 million in 2024 and is expected to grow at a CAGR of 13.42%. North America's leadership in this market is attributed to rising cancer cases and technological advancements.
AI Analysis | Feedback
American Shared Hospital Services (AMS) is expected to drive future revenue growth over the next 2-3 years through several strategic initiatives focused on expanding its direct patient care services, technological advancements, and geographical footprint.
- Expansion into Direct Patient Care Services through Strategic Acquisitions: American Shared Hospital Services is actively transitioning from primarily leasing equipment to becoming a direct provider of radiation therapy treatment services. This shift is a significant revenue driver, exemplified by the acquisition of a 60% majority interest in three Rhode Island radiation therapy centers in May 2024. This acquisition led to substantial revenue growth in the direct patient services segment, with a 253% increase in fiscal year 2024 and a 224% increase in the first quarter of 2025. The company continues to focus on business development and operational efficiencies within this segment.
- Growth in Proton Beam Radiation Therapy (PBRT): The company is investing in the expansion of its Proton Beam Radiation Therapy offerings. A notable driver is the Certificate of Need (CON) approval received in December 2024 for a subsidiary to construct and operate a freestanding PBRT system in Johnston, Rhode Island. This facility is anticipated to begin treating patients in 36-39 months and represents a significant technological advancement in cancer care, creating greater access to this specialized treatment in the Northeast.
- International Expansion, Particularly in Latin America: American Shared Hospital Services is expanding its international presence as a key revenue growth strategy. This includes the launch of new radiation therapy operations in Puebla, Mexico, which contributed to significant growth in the direct patient services segment in 2024. Additionally, the company expects long-term growth from a new Esprit Gamma Knife center being installed in Guadalajara, Mexico, with operations projected to start in late 2025 or the second quarter of 2026. The company also noted revenue growth in Peru and Ecuador in fiscal year 2024.
- Modernization and Strategic Placement of Gamma Knife Systems: While the equipment leasing segment, including Gamma Knife operations, has seen some fluctuations, the company is focused on upgrading existing Gamma Knife systems and securing long-term lease extensions with health systems. For instance, a 10-year extension for an upgraded Gamma Knife system has been signed. This strategy aims to sustain and enhance revenue from its core Gamma Knife business through modern technology and strategic placements like the new Esprit in Guadalajara.
AI Analysis | Feedback
Share Repurchases
American Shared Hospital Services has shown minimal to no significant share repurchases over the last 3-5 years. The trailing twelve months (TTM) Buyback Yield stands at 0%. Over the past five years, the median Buyback Yield for the company was 0%, with the highest recorded at 0% and the lowest at -0.04% in March 2022.
Share Issuance
The number of shares outstanding for American Shared Hospital Services increased by 1.57% in one year. As of December 30, 2024, the company had 6.54 million shares outstanding.
Capital Expenditures
American Shared Hospital Services reported capital expenditures of -$14.28 million in the last 12 months. The latest trailing twelve months (TTM) Capital Expenditure to Operating Cash Flow (CapEx/OCF) stands at 343.06%. Over the past five years, the average CapEx/OCF was 345.43%, reaching a high of 4576.65% on December 31, 2024. These capital expenditures are primarily focused on acquiring and maintaining radiosurgery and radiation therapy equipment, such as Gamma Knife and proton beam radiation therapy systems, which are central to the company's leasing business.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| American Shared Hospital Services Earnings Notes | 12/16/2025 | |
| null | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to AMS.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 167.61 |
| Mkt Cap | 10.0 |
| Rev LTM | 11,517 |
| Op Inc LTM | 1,245 |
| FCF LTM | 550 |
| FCF 3Y Avg | 522 |
| CFO LTM | 1,249 |
| CFO 3Y Avg | 1,108 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.8% |
| Rev Chg 3Y Avg | 8.6% |
| Rev Chg Q | 8.6% |
| QoQ Delta Rev Chg LTM | 2.0% |
| Op Inc Chg LTM | 13.6% |
| Op Inc Chg 3Y Avg | 12.7% |
| Op Mgn LTM | 11.6% |
| Op Mgn 3Y Avg | 12.6% |
| QoQ Delta Op Mgn LTM | -0.0% |
| CFO/Rev LTM | 11.1% |
| CFO/Rev 3Y Avg | 11.9% |
| FCF/Rev LTM | 4.5% |
| FCF/Rev 3Y Avg | 4.9% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 10.0 |
| P/S | 0.7 |
| P/Op Inc | 5.4 |
| P/EBIT | 4.4 |
| P/E | 8.2 |
| P/CFO | 6.4 |
| Total Yield | 5.9% |
| Dividend Yield | 0.1% |
| FCF Yield 3Y Avg | 4.4% |
| D/E | 0.7 |
| Net D/E | 0.6 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -5.3% |
| 3M Rtn | -13.8% |
| 6M Rtn | -7.4% |
| 12M Rtn | 13.1% |
| 3Y Rtn | 40.2% |
| 1M Excs Rtn | -14.0% |
| 3M Excs Rtn | -20.2% |
| 6M Excs Rtn | -19.2% |
| 12M Excs Rtn | -18.6% |
| 3Y Excs Rtn | -43.5% |
Price Behavior
| Market Price | $1.89 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 09/07/1984 | |
| Distance from 52W High | -37.8% | |
| 50 Days | 200 Days | |
| DMA Price | $1.73 | $2.16 |
| DMA Trend | down | down |
| Distance from DMA | 9.2% | -12.5% |
| 3M | 1YR | |
| Volatility | 81.7% | 57.8% |
| Downside Capture | -0.31 | 0.00 |
| Upside Capture | -113.24 | -46.74 |
| Correlation (SPY) | -17.3% | -5.4% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -3.47 | -1.14 | -0.95 | -0.58 | -0.19 | 0.04 |
| Up Beta | -5.87 | -5.19 | -4.35 | -2.89 | -1.30 | -0.01 |
| Down Beta | 0.10 | 0.14 | 0.64 | 0.13 | 0.55 | 0.09 |
| Up Capture | -111% | -97% | -83% | -45% | -22% | -2% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 7 | 12 | 21 | 42 | 96 | 319 |
| Down Capture | 995% | 174% | 107% | 71% | 67% | 41% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 12 | 24 | 35 | 61 | 126 | 373 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AMS | |
|---|---|---|---|---|
| AMS | -35.2% | 57.6% | -0.54 | - |
| Sector ETF (XLV) | 8.6% | 15.4% | 0.34 | -12.3% |
| Equity (SPY) | 28.1% | 12.5% | 1.78 | -4.8% |
| Gold (GLD) | 42.9% | 26.9% | 1.30 | -5.4% |
| Commodities (DBC) | 48.6% | 18.0% | 2.14 | -0.5% |
| Real Estate (VNQ) | 13.6% | 13.5% | 0.70 | -3.4% |
| Bitcoin (BTCUSD) | -22.4% | 41.7% | -0.50 | 3.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AMS | |
|---|---|---|---|---|
| AMS | -7.1% | 49.6% | 0.02 | - |
| Sector ETF (XLV) | 4.8% | 14.6% | 0.15 | 1.7% |
| Equity (SPY) | 12.9% | 17.1% | 0.59 | 10.7% |
| Gold (GLD) | 21.2% | 17.9% | 0.96 | -2.3% |
| Commodities (DBC) | 13.5% | 19.1% | 0.58 | 5.4% |
| Real Estate (VNQ) | 3.6% | 18.8% | 0.09 | 7.2% |
| Bitcoin (BTCUSD) | 8.5% | 56.0% | 0.36 | 10.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AMS | |
|---|---|---|---|---|
| AMS | -0.6% | 60.2% | 0.23 | - |
| Sector ETF (XLV) | 9.2% | 16.5% | 0.45 | 11.1% |
| Equity (SPY) | 15.0% | 17.9% | 0.72 | 14.4% |
| Gold (GLD) | 13.4% | 15.9% | 0.70 | 2.3% |
| Commodities (DBC) | 9.5% | 17.7% | 0.45 | 7.1% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.24 | 12.2% |
| Bitcoin (BTCUSD) | 68.1% | 66.9% | 1.07 | 6.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/31/2026 | -19.9% | -23.8% | -26.0% |
| 11/13/2025 | -1.8% | -7.6% | -4.9% |
| 8/13/2025 | 0.2% | -4.7% | -3.5% |
| 4/4/2025 | -5.3% | -9.7% | -7.7% |
| 11/13/2024 | 8.4% | 6.0% | 21.1% |
| 8/14/2024 | -3.2% | -2.3% | -2.8% |
| 3/28/2024 | 9.7% | 9.3% | 17.8% |
| 11/13/2023 | 6.1% | 11.1% | 8.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 13 | 11 | 9 |
| # Negative | 6 | 8 | 10 |
| Median Positive | 2.3% | 5.5% | 8.2% |
| Median Negative | -2.9% | -5.2% | -4.2% |
| Max Positive | 12.5% | 13.2% | 35.5% |
| Max Negative | -19.9% | -23.8% | -26.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/31/2026 | 10-K |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/13/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 04/04/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 04/01/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/12/2023 | 10-Q |
| 12/31/2022 | 03/31/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.